MEDI-493 FOR PREMATURE INFANTS AND INFANTS WITH BRONCHOPULMONARY DYSPLASIA

MEDI-493 适用于早产儿和支气管肺发育不良婴儿

• 批准号: 6278004
• 负责人: LEONARD E. WEISMAN
• 金额: $ 2.57万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278004
• 关键词: antiviral agents; bronchopulmonary dysplasia; chemoprevention; clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; immunotherapy; monoclonal antibody; pharmacokinetics; premature infant human; respiratory infections; respiratory syncytial virus

This study will evaluate the safety and pharmacokinetics of MEDI-493 in premature infants and infants with bronchopulmonary dysplasia who are at high risk for RSV infection. ("D" protocol)

本研究将评估 MEDI-493 在临床中的安全性和药代动力学 早产儿和患有支气管肺发育不良的婴儿 RSV 感染的高风险。 （“D”协议）